Your browser doesn't support javascript.
loading
Detection of Polioviruses Type 2 among Migrant Children Arriving to the Russian Federation from a Country with a Registered Poliomyelitis Outbreak.
Ivanova, Olga E; Eremeeva, Tatiana P; Baykova, Olga Y; Krasota, Alexandr Y; Yakovchuk, Elizaveta V; Shustova, Elena Y; Malyshkina, Lyudmila P; Mustafina, Aida N-I; Mikhailova, Yulia M; Chirova, Alina V; Cherepanova, Evgeniya A; Morozova, Nadezhda S; Gladkikh, Anna S; Dolgova, Anna S; Dedkov, Vladimir G; Totolian, Areg A; Kozlovskaya, Liubov I.
Afiliação
  • Ivanova OE; Federal State Autonomous Scientific Institution "Chumakov Federal Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences" (Institute of Poliomyelitis) (FSASI "Chumakov FSC R&D IBP RAS"), 108819 Moscow, Russia.
  • Eremeeva TP; Department of Organization and Technology of Production of Immunobiological Preparations, Institute for Translational Medicine and Biotechnology, First Moscow State Medical University (Sechenov University), 119048 Moscow, Russia.
  • Baykova OY; Federal State Autonomous Scientific Institution "Chumakov Federal Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences" (Institute of Poliomyelitis) (FSASI "Chumakov FSC R&D IBP RAS"), 108819 Moscow, Russia.
  • Krasota AY; Federal State Autonomous Scientific Institution "Chumakov Federal Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences" (Institute of Poliomyelitis) (FSASI "Chumakov FSC R&D IBP RAS"), 108819 Moscow, Russia.
  • Yakovchuk EV; Federal State Autonomous Scientific Institution "Chumakov Federal Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences" (Institute of Poliomyelitis) (FSASI "Chumakov FSC R&D IBP RAS"), 108819 Moscow, Russia.
  • Shustova EY; Federal State Autonomous Scientific Institution "Chumakov Federal Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences" (Institute of Poliomyelitis) (FSASI "Chumakov FSC R&D IBP RAS"), 108819 Moscow, Russia.
  • Malyshkina LP; Federal State Autonomous Scientific Institution "Chumakov Federal Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences" (Institute of Poliomyelitis) (FSASI "Chumakov FSC R&D IBP RAS"), 108819 Moscow, Russia.
  • Mustafina AN; Federal State Autonomous Scientific Institution "Chumakov Federal Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences" (Institute of Poliomyelitis) (FSASI "Chumakov FSC R&D IBP RAS"), 108819 Moscow, Russia.
  • Mikhailova YM; Federal State Autonomous Scientific Institution "Chumakov Federal Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences" (Institute of Poliomyelitis) (FSASI "Chumakov FSC R&D IBP RAS"), 108819 Moscow, Russia.
  • Chirova AV; Federal Budgetary Health Institution "Federal Center of Hygiene and Epidemiology" of the Federal Office for Inspectorate in the Field of Customers and Human Well-Being Protection" (FBHI FCH&E), 117105 Moscow, Russia.
  • Cherepanova EA; Federal Budgetary Health Institution "Federal Center of Hygiene and Epidemiology" of the Federal Office for Inspectorate in the Field of Customers and Human Well-Being Protection" (FBHI FCH&E), 117105 Moscow, Russia.
  • Morozova NS; Federal Budgetary Health Institution "Federal Center of Hygiene and Epidemiology" of the Federal Office for Inspectorate in the Field of Customers and Human Well-Being Protection" (FBHI FCH&E), 117105 Moscow, Russia.
  • Gladkikh AS; Federal Budgetary Health Institution "Federal Center of Hygiene and Epidemiology" of the Federal Office for Inspectorate in the Field of Customers and Human Well-Being Protection" (FBHI FCH&E), 117105 Moscow, Russia.
  • Dolgova AS; Saint-Petersburg Pasteur Institute, Federal Service on Consumers' Rights Protection and Human Well-Being Surveillance, 197101 Saint-Petersburg, Russia.
  • Dedkov VG; Saint-Petersburg Pasteur Institute, Federal Service on Consumers' Rights Protection and Human Well-Being Surveillance, 197101 Saint-Petersburg, Russia.
  • Totolian AA; Saint-Petersburg Pasteur Institute, Federal Service on Consumers' Rights Protection and Human Well-Being Surveillance, 197101 Saint-Petersburg, Russia.
  • Kozlovskaya LI; Martsinovsky Institute of Medical Parasitology, Tropical and Vector Borne Diseases, First Moscow State Medical University (Sechenov University), 119048 Moscow, Russia.
Vaccines (Basel) ; 12(7)2024 Jun 28.
Article em En | MEDLINE | ID: mdl-39066356
ABSTRACT
The widespread use of the oral poliovaccine from Sabin strains (tOPV) radically reduced poliomyelitis incidence worldwide. However, OPV became a source of neurovirulent vaccine-derived polioviruses (VDPVs). Currently, circulating type 2 VDPVs (cVDPV2) are the leading cause of poliomyelitis. The novel OPV type 2 vaccine (nOPV2), based on genetically modified Sabin strain with increased genetic stability and reduced risk of cVDPV formation, has been used to combat cVDPV2 outbreaks, including one in Tajikistan in 2021. In order to identify the importation of cVDPV2 and nOPV2-derivates, stool samples from 12,127 healthy migrant children under 5 years of age arriving from Tajikistan were examined in Russia (March 2021-April 2022). Viruses were isolated in cell culture and identified via intratype differentiation RT-PCR, VP1 and whole-genome sequencing. cVDPV2 isolates closely related with the Tajikistan one were isolated from two children, and nOPV2-derived viruses were detected in specimens from 106 children from 37 regions of Russia. The duration of nOPV2 excretion ranged from 24 to 124 days post-vaccination. nOPV2 isolates contained 27 mutations per genome (0.36%) on average, with no critical genetic changes, which confirms the genetic stability of nOPV2 during field use. The possibility of epidemiologically significant poliovirus introduction into polio-free countries has been confirmed. The screening of special populations, including migrants, is required to maintain epidemiological well-being.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Vaccines (Basel) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Federação Russa

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Vaccines (Basel) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Federação Russa